Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
US10981892B2 · kind B2 · utility
1Cited by
11References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 10, 2020 |
| Grant date | Apr 20, 2021 |
| Priority date | — |
| Expiry date | Jun 10, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F9/65583
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The aryl sulfonamide compounds of this invention have powerful and cell-type specific Bcl inhibitory activity. Selected compounds in this class promote apoptosis in senescent cells, and are being developed for treating senescent-related conditions. Selected compounds in this class promote apoptosis in cancer cells, and can be developed as chemotherapeutic agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.